GSK Aims To Launch 13 Blockbusters In Five Years
Immuno-Oncology Central To Ambitions
GSK achieved a first-in-class market oncology launch in 2020, but will have to increase that hit rate in order to fulfil its blockbuster ambitions.
You may also be interested in...
Join us for an audio catch-up on the latest key developments in the global biopharma industry, as reported by Scrip's global team, in this mini podcast version of Five Must-Know Things.
US FDA-approved belantamab mafodotin is indicated for heavily pre-treated multiple myeloma and has a list price of $23,900 per month. Its REMS could limit initial uptake, but response rates have been encouraging.
Deal brings in new funding and commercial partner for CureVac, and gives GSK greater stake in fast-developing mRNA field.